Search

Chromium

Chromium chloride is available as an intravenous injection for use as a supplement to intravenous solutions given for total parenteral nutrition (TPN) [FDA Label].

Chymopapain

[A32688] Chymopapain was developed by Chart Medcl and FDA approved on November 10, 1982. It is currently discontinued.[L2487] … Chymopapain was first isolated in 1941 from the crude latex derived from the fruit of Carica papaya by squeezing the green papaya while on the plant prior to harvest.

ALGRX 1207

It was being developed by Anesiva, but trials have halted. … ALGRX 1207 is a topical local anesthetic that acts by binding to the fast sodium channel.

Interferon alfa

Interferon alfa contains several naturally occurring IFN-α subtypes and is purified by affinity chromatography.

Insulin human

the US markets [A176005]. … While still available in the US, Afrezza has had similar concerns associated with its use, and had an FDA "black box" warning added to it to warn about use in patients with chronic lung disease.

Encainide

The manufacturer of Enkaid capsules voluntarily withdrew the product from the US market on December 16, 1991.

Methoxyamine

Fondaparinux

Once bound to heparin or HS, the anticoagulant activity of ATIII is potentiated by 1000-fold. Fondaparinux potentiates the neutralizing action of ATIII on activated Factor X 300-fold. … undergoing abdominal surgery who are are at high risk of thromboembolic complications; in the treatment of deep vein thrombosis (DVT) and pumonary embolism (PE); in the management of unstable angina (UA

Nialamide

Withdrawn from the Canadian, US, and UK markets in 1963 due to interactions with food products containing tyrosine.

Amsacrine

It produces consistent but acceptable myelosuppression and cardiotoxic effects. … It is effective in the treatment of acute leukemias and malignant lymphomas, but has poor activity in the treatment of solid tumors.